Selecting a Treatment Regimen Table 7. Some recommended regimens* for testosterone replacement therapy
Î75–100 mg of testosterone enanthate or cypionate administered IM weekly, or 150–200 mg administered every 2 wk
ÎOne or two 5-mg nongenital, testosterone patches applied nightly over the skin of the back, thigh, or upper arm, away from pressure areas
Î5–10 g of a 1% testosterone gel applied daily over a covered area of nongenital skin (patients should wash hands after application)
Î30 mg of a bioadhesive, buccal testosterone tablet applied to buccal mucosa twice daily
Î3–6 testosterone pellets implanted subcutaneously; the dose and regimen vary with the formulation used
*These regimens should be viewed as suggestions for initiation of testosterone replacement therapy. Dose and regimen should be adjusted on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost. (2⎟ ⊕⊕)
Endocrine Society Guidelines for TRT Monitoring Baseline Each Visit
3–6 Months
T Levels Hematocrit* DRE† PSA† Symptom Response Adverse Events
Formulation-Specific Adverse Events
BMD of Lumbar Spine/ Femoral Neck‡
* If Hct > 54%, D/C treatment until Hct at a safe level. Evaluate patient for hypoxia and sleep apnea. Depending upon age and race of patient.
Reinitiate therapy at a lower dose. †
‡For patients with osteoporosis or low trauma fracture.
Yearly
Q 1–2 Years
6
